Group 1 - The core viewpoint of the news is that Kehua Bio's stock has experienced a decline in performance, with a significant drop in revenue and net profit in the latest quarterly report [1] - As of May 6, Kehua Bio's closing price was 5.76 yuan, up 1.41%, with a market-to-book ratio of 0.91, marking a new low in 20 days and a total market value of 2.962 billion yuan [1] - The company reported a revenue of 388 million yuan for Q1 2025, a year-on-year decrease of 12.50%, and a net loss of approximately 53.26 million yuan, a year-on-year decline of 84.79%, with a gross profit margin of 37.39% [1] Group 2 - Kehua Bio's main business includes the research, production, and sales of in vitro diagnostic reagents and medical testing instruments, with key products in biochemical diagnosis, immunodiagnosis, and molecular diagnosis [1] - The company has received several honors, including the National Science and Technology Progress Award (Second Class), and is recognized as a national high-tech enterprise and a pilot enterprise for intellectual property [1] - In comparison to industry averages, Kehua Bio's price-to-earnings ratio (TTM) is -4.45, and its market-to-book ratio is 0.91, indicating a lower valuation compared to the industry average [2]

Core Viewpoint - The company, Shanghai Kehua Bio-engineering Co., Ltd., has released its first quarter report for 2025, ensuring the accuracy and completeness of the financial information presented [11][17]. Financial Data - The first quarter report has not been audited [3][8]. - The company does not require retrospective adjustments or restatements of previous accounting data [4]. - Non-recurring gains and losses include a refund of personal income tax handling fees [4]. Shareholder Information - As of the reporting period, the company holds 13,696,600 shares in its repurchase account, accounting for 2.66% of the total share capital [6]. Board and Supervisory Meetings - The 13th meeting of the 10th Board of Directors was held on April 29, 2025, with all 9 directors present, including 3 independent directors [10]. - The Board approved the first quarter report, confirming it accurately reflects the company's financial status without any misleading statements [11]. - The 9th meeting of the 10th Supervisory Board also confirmed the report's accuracy and completeness [17].

前十大流通股东累计持有： 13121.72万股，累计占流通股比： 25.51%，较上期变化： -82.69万股。 | 名称 持有数量(万股) | | 占总股本比例 | 增减情况(万 | | --- | --- | --- | --- | | | | (%) | 股) | | 珠海保联投资控股有限公司 | 7014.72 | 13.64 | 不变 | | 西安致同本益企业管理合伙企业(有限合伙) | 2571.59 | 5.00 | 不变 | | 湾区产融投资(广州)有限公司 | 1031.72 | 2.01 | 不变 | | 上海璞真私募基金管理有限公司-璞真若愚2号私募证 券投资基金 | 547.00 | 1.06 | 不变 | | 林腾光 | 441.48 | 0.86 | 不变 | | 胡宏伟 | 357.00 | 0.69 | 15.00 | | 王成华 | 333.96 | 0.65 | 61.28 | | 李伟奇 | 301.00 | 0.59 | -1.00 | | 香港中央结算有限公司 | 300.49 | 0.58 | -108.15 | | 孙宇羿 | 222.76 | 0.43 | 新进 ...

第十届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 上海科华生物工程股份有限公司（以下简称"公司"）第十届监事会第九次 会议（以下简称"本次会议"或"会议"）通知于2025年4月25日以邮件方式送达 各位监事，会议于2025年4月29日以通讯表决方式召开。本次会议应出席监事3人， 实际出席监事3人。本次会议由监事会主席易超先生主持，会议的召开符合《中 华人民共和国公司法》、《上海科华生物工程股份有限公司章程》和《上海科华生 物工程股份有限公司监事会议事规则》的有关规定。 二、监事会会议审议情况 证券代码：002022 证券简称：科华生物 公告编号：2025-028 债券代码：128124 债券简称：科华转债 上海科华生物工程股份有限公司 （一）审议通过《关于<2025 年第一季度报告>的议案》 三、备查文件 1、第十届监事会第九次会议决议。 特此公告。 上海科华生物工程股份有限公司监事会 2025年4月30日 经审议，监事会认为：公司董事会编制和审核《2025 年第一季度报告》的程 序符合相关法律、行政法规的 ...

公司《2025年第一季度报告》真实、准确、完整地反映了公司2025年第一季 度的财务状况和经营成果，不存在虚假记载、误导性陈述和重大遗漏。 证券代码：002022 证券简称：科华生物 公告编号：2025-027 债券代码：128124 债券简称：科华转债 上海科华生物工程股份有限公司 第十届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 上海科华生物工程股份有限公司（以下简称"公司"）第十届董事会第十三 次会议（以下简称"本次会议"或"会议"）通知于2025年4月25日以邮件方式送 达全体董事、监事及高级管理人员，会议于2025年4月29日以通讯表决的方式召 开。本次会议应参会董事9人，实际参会董事9人（包含3名独立董事）。本次会议 由公司董事长李明先生主持，会议的召开符合《中华人民共和国公司法》、《上海 科华生物工程股份有限公司章程》和《上海科华生物工程股份有限公司董事会议 事规则》的有关规定。 二、董事会会议审议情况 （一）审议通过《关于<2025年第一季度报告>的议案》 具体详见公司于同日在《证券时报》 ...

Financial Performance - The company's revenue for Q1 2025 was ¥387,883,698.30, a decrease of 12.50% compared to ¥443,303,887.87 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥53,259,784.78, representing an 84.79% increase in loss compared to a loss of ¥28,821,454.12 in the previous year[4] - The basic and diluted earnings per share were both -¥0.1036, reflecting an 82.39% increase in loss compared to -¥0.0568 in the same period last year[4] - Net profit for the period was a loss of ¥53,745,471.97, compared to a loss of ¥21,682,586.79 in the previous period, indicating a worsening of approximately 147.5%[16] - The company reported a total comprehensive loss of ¥41,836,296.38, compared to a loss of ¥30,734,726.73 in the previous period[16] Cash Flow - The net cash flow from operating activities improved to -¥51,291,981.79, a 64.28% increase compared to -¥143,612,182.50 in the same period last year[4] - Total cash inflow from operating activities decreased to 428,107,002.27 CNY, down from 451,797,344.65 CNY year-over-year[18] - Cash outflow from operating activities decreased to 479,398,984.06 CNY, compared to 595,409,527.15 CNY in the previous period[18] - The net increase in cash and cash equivalents for the current period is -77,316,974.22 CNY, an improvement from -239,639,024.47 CNY in the previous period[18] - The ending balance of cash and cash equivalents is 787,309,260.67 CNY, down from 1,376,357,042.59 CNY in the previous period[18] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,195,708,595.15, a decrease of 0.77% from ¥5,236,128,052.84 at the end of the previous year[4] - Total liabilities increased marginally to ¥1,258,305,418.76 from ¥1,253,747,330.56[14] - The equity attributable to shareholders decreased by 1.23% to ¥3,308,485,682.12 from ¥3,349,826,403.95 at the end of the previous year[4] - The company's total assets amounted to ¥5,195,708,595.15, slightly down from ¥5,236,128,052.84[14] Shareholder Information - Total number of common shareholders at the end of the reporting period is 42,590[9] - The largest shareholder, Zhuhai Baolian Investment Holding Co., Ltd., holds 13.64% of shares, totaling 70,147,179 shares[9] - The company has a share repurchase account holding 13,696,600 shares, representing 2.66% of the total share capital[9] Operating Costs and Expenses - Total operating costs decreased to ¥443,013,698.68 from ¥482,388,247.21, a reduction of about 8.1% year-over-year[15] - Research and development expenses were ¥44,061,435.78, down from ¥47,231,870.73, reflecting a decrease of approximately 4.6%[15] - The company experienced a 54.68% decrease in financial expenses, which amounted to ¥2,756,037.15 compared to ¥6,081,459.37 in the previous year[7] Impairment and Gains - The company reported a significant increase in credit impairment losses, which rose by 368.32% to -¥4,970,053.18 compared to -¥1,061,254.57 in the previous year[7] - The company recorded a 90.19% increase in asset disposal gains, amounting to ¥1,077,766.10 compared to ¥566,673.46 in the previous year[7] Accounting and Audit - The company has not undergone an audit for the first quarter report[19] - The new accounting standards will be implemented starting from 2025[19]

Group 1 - The core point of the article is that Kehua Bio (002022) reported a decline in revenue and an increase in net loss for the first quarter of 2025 compared to the same period last year [1] Group 2 - The company's operating revenue for Q1 2025 was 388 million yuan, representing a year-on-year decrease of 12.50% [1] - The net loss for the first quarter was 53.26 million yuan, compared to a net loss of 28.82 million yuan in the same quarter last year [1]

Shareholding Reduction Announcements - MEI TUNG (CHINA) LIMITED plans to reduce its shareholding in Helen Zhe by up to 22.09 million shares, representing 2.12% of the total share capital after excluding repurchased shares [1] - Shandong Railway Development Fund plans to reduce its shareholding in Century Rui Er by up to 17.55 million shares, representing 3% of the total share capital [1] - Wu Baigeng plans to reduce his shareholding in Pinwo Food by up to 2.97 million shares, representing 3% of the total share capital [1] - Huayuan International Land Port Group plans to reduce its shareholding in Phoenix Shipping by up to 30.36 million shares, representing 3% of the total share capital [3] Financial Performance Reports - United Chemical reported a revenue of 535 million yuan for 2024, a year-on-year increase of 24.80%, and a net profit of 56.43 million yuan, up 66.81% [5] - Huitong Technology achieved a revenue of 662 million yuan, a year-on-year increase of 11.84%, and a net profit of 108 million yuan, up 9.30% [7] - Guangji Pharmaceutical reported a revenue of 639 million yuan, a year-on-year decrease of 13.42%, and a net loss of 295 million yuan [8] - Anshuo Information achieved a revenue of 990 million yuan, a year-on-year increase of 11.53%, and a net profit of 15.09 million yuan, up 132.78% [9] - Yifan Pharmaceutical reported a revenue of 5.16 billion yuan, a year-on-year increase of 26.84%, and a net profit of 386 million yuan, up 170.04% [10] - Hongri Pharmaceutical reported a revenue of 5.78 billion yuan, a year-on-year decrease of 5.34%, and a net profit of 21.47 million yuan, down 95.76% [11] - Zhonglan Environmental reported a revenue of 646 million yuan, a year-on-year decrease of 22.75%, and a net profit of 13.10 million yuan, down 36.12% [13] - Feilu Co. reported a revenue of 518 million yuan, a year-on-year decrease of 37.16%, and a net loss of 140 million yuan [14] - China Great Wall reported a revenue of 14.20 billion yuan, a year-on-year increase of 5.83%, and a net loss of 1.48 billion yuan [15] - Nanshan A reported a revenue of 15.45 billion yuan, a year-on-year decrease of 15.06%, and a net profit of 267 million yuan, down 83.89% [16] - Yawen Co. reported a revenue of 2.06 billion yuan, a year-on-year increase of 6.70%, and a net profit of 75 million yuan, down 24.13% [17] - Jinlong Co. reported a revenue of 663 million yuan, a year-on-year increase of 245.16%, and a net loss of 89.23 million yuan [18] - Nanshan Holdings reported a revenue of 8.40 billion yuan, a year-on-year decrease of 30.35%, and a net loss of 1.77 billion yuan [20] - Hengfeng Information reported a revenue of 227 million yuan, a year-on-year decrease of 53.07%, and a net loss of 86.80 million yuan [21] - Wantong Technology reported a revenue of 1.21 billion yuan, a year-on-year increase of 19.58%, and a net profit of 36.92 million yuan, up 147.08% [22] - Kehua Bio reported a revenue of 1.76 billion yuan, a year-on-year decrease of 27.55%, and a net loss of 641 million yuan [23] - Dongfang Tower reported a revenue of 4.20 billion yuan, a year-on-year increase of 4.79%, and a net profit of 564 million yuan, down 10.97% [24] - Yanpai Co. reported a revenue of 785 million yuan, a year-on-year increase of 8.75%, and a net profit of 42.18 million yuan, down 35.72% [25] - Yongli Co. reported a revenue of 2.24 billion yuan, a year-on-year increase of 10.69%, and a net profit of 22.30 million yuan, down 40.73% [26]

内部控制审计报告 上海科华生物工程股份有限公司 容诚审字[2025]200Z2350 号 容诚会计师事务所(特殊普通合伙) 中国·北京 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 内部控制审计报告 容诚审字[2025]200Z2350 号 上海科华生物工程股份有限公司全体股东： 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表 审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为，科华生物于 2024 年 12 月 3 ...

关于上海科华生物工程股份有限公司 2024 年度营业收入扣除情况的专项审核报告 2024 年度营业收入扣除情况的 专项审核报告 上海科华生物工程股份有限公司 容诚专字[2025]200Z0639 号 容诚会计师事务所(特殊普通合伙) 中国·北京 | | | | 序号 | 内 | 容 | 页码 | | --- | --- | --- | --- | | 1 | 营业收入扣除情况的专项审核报告 | | 1-3 | | 2 | 营业收入扣除情况表 | | 4-5 | 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 容诚专字[2025]200Z0639 号 上海科华生物工程股份有限公司全体股东： 我们接受委托，按照中国注册会计师审计准则审计了上海科华生物工程股份 有限公司（以下简称科华生物）2024 年度财务报表，并于 2025 年 4 月 ...